Versanis Bio develops treatments targeting activin type II receptors to regulate fat and muscle metabolism, addressing obesity and cardiometabolic diseases. By blocking activin signaling, the company aims to reduce visceral fat accumulation and promote muscle growth, improving body composition and metabolic health for individuals affected by these conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Obesity and cardiometabolic diseases are driven by imbalances in fat and muscle metabolism, particularly the accumulation of visceral fat and the inhibition of muscle growth. Current treatments often fail to address the underlying mechanisms regulating both fat and muscle, leading to suboptimal improvements in body composition and metabolic health. In cardiac muscle, elevated activin signaling contributes to contractile protein degradation and disease severity in heart failure.
Solution
Versanis Bio is developing treatments that target activin type II receptors (ActRII) to regulate fat and muscle metabolism, offering a novel approach to combat obesity and related cardiometabolic disorders. By selectively blocking activin signaling, the company aims to reduce lipid storage and visceral fat accumulation, while simultaneously promoting muscle growth and preventing muscle atrophy. This dual-action mechanism has the potential to improve body composition, enhance metabolic health, and reverse damage to the heart by preventing contractile protein degradation. Versanis's approach combines expertise in activin biology with insights into incretin biology to develop transformative therapies.
Target Audience
The primary target audience includes individuals affected by obesity, cardiometabolic diseases, and heart failure, as well as healthcare providers specializing in these conditions.
Features
- Targets activin type II receptors (ActRII) found in both fat and muscle cells
- Blocks activin signaling to directly inhibit lipid storage and visceral fat accumulation
- Promotes muscle growth and inhibits muscle atrophy, improving body composition
- Addresses contractile protein degradation in cardiac muscle associated with heart failure
- Aims to improve metabolic health by regulating fat and muscle metabolism